Research and Development Expenses Breakdown: Teva Pharmaceutical Industries Limited vs Dr. Reddy's Laboratories Limited

R&D Spending Trends: Teva vs. Dr. Reddy's (2014-2024)

__timestampDr. Reddy's Laboratories LimitedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014124020000001488000000
Thursday, January 1, 2015174490000001525000000
Friday, January 1, 2016178340000002111000000
Sunday, January 1, 2017195510000001848000000
Monday, January 1, 2018182650000001213000000
Tuesday, January 1, 2019156070000001010000000
Wednesday, January 1, 202015410000000997000000
Friday, January 1, 202116541000000967000000
Saturday, January 1, 202217482000000838000000
Sunday, January 1, 202319381000000953000000
Monday, January 1, 202422873000000998000000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited have demonstrated contrasting approaches to R&D investment.

Dr. Reddy's Laboratories: A Steady Climb

From 2014 to 2023, Dr. Reddy's Laboratories consistently increased its R&D spending, peaking in 2024 with a remarkable 84% growth from its 2014 levels. This steady climb underscores the company's commitment to innovation and its strategic focus on expanding its product pipeline.

Teva Pharmaceutical: A Volatile Journey

In contrast, Teva's R&D expenses have shown volatility, with a notable peak in 2016. However, by 2023, their investment had decreased by approximately 36% from the 2016 high. This fluctuation may reflect strategic shifts or financial constraints.

The data highlights the diverse strategies these pharmaceutical giants employ to navigate the ever-evolving landscape of drug development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025